Biocryst Pharmaceuticals\' firstofitskind oral therapy for a rare genetic disease successfully reduced the rate of swelling attacks experienced by patients compared to placebo. But the benefit demonstrated was relatively small. httpsbuff.ly2V

Biocryst Pharmaceuticals' first-of-its-kind oral therapy for a rare, genetic disease successfully reduced the rate of swelling “attacks” experienced by patients compared to placebo. But the benefit demonstrated was relatively small. https://buff.ly/2V

Biocryst Pharmaceuticals' first-of-its-kind oral therapy for a rare, genetic disease successfully reduced the rate of swelling “attacks” experienced by patients compared to placebo. But the benefit demonstrated was relatively small. https://buff.ly/2VEGKsL 

More From BioPortfolio on "Biocryst Pharmaceuticals' first-of-its-kind oral therapy for a rare, genetic disease successfully reduced the rate of swelling “attacks” experienced by patients compared to placebo. But the benefit demonstrated was relatively small. https://buff.ly/2V"